E. A. Pavlovskaya

E. A. Pavlovskaya

Auto-generated profile, based on publicly available information

E. A. Pavlovskaya

N. N. Petrov National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Medical Visualization
Verified
Journal Article
Open access
PDF file
EPE. A. Pavlovskaya
E. A. Pavlovskaya
SBSergey S. Bagnenko
Sergey S. Bagnenko
IBIlya A. Burovik
Ilya A. Burovik
EBEkaterina A. Busko
Ekaterina A. Busko
STStanislav A. Tiatkov
Stanislav A. Tiatkov
IBIgor V. Berlev
Igor V. Berlev
The present paper reports available modern data about the safety of medical visualization, including US, MRI, CT, PET and scintigraphy. In all accessed papers, objects are pregnant women and fetuses – the most vulnerable of all groups of patients. We summarize data concerning exposure to radiodiagnostic procedures during pregnancy and approaches to diminish the potential risk. We analyzed articles published between 2003 and 2023 using PubMed and Google Scholar. Keywords included: MR-safety, pregnancy, CT, MRI, US, scintigraphy. The list of found articles consisted of more the 2000 items. We analyzed more than 100 articles in Russian and English and included 63 items in the current review. Primarily we dealt with clinical guidelines based on randomized trials on the safety of radiological methods during pregnancy. Hopefully, presented information, including the latest international recommendations, will help clinicians and patients pursue realistic and informed approaches and minimize anxiety.

14 April 2025 in Diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
PBP. V. Balakhnin
P. V. Balakhnin
AKA. G. Karakhanova
A. G. Karakhanova
AKA. V. Kulish
A. V. Kulish
EPE. A. Pavlovskaya
E. A. Pavlovskaya
PGP. Yu. Grishko
P. Yu. Grishko
ЕБЕ. А. Бусько
Е. А. Бусько
INTRODUCTION: Carbon dioxide (СО2) is a safe contrast agent for patients requiring endovascular and angiography-assisted procedures due to lack of renal toxicity and allergic potential. It is highly important in patients with renal failure and allergies to iodinated contrast agents.OBJECTIVE: To demonstrate a clinical case of percutaneous biopsy guided with the flat-detector computed tomography (FDCT) CO2 arteriohepaticography in the patient with suspected metastatic lesion of the liver, history of cervical squamous cell carcinoma and chronic kidney disease (CKD).MATERIALS AND METHODS: A patient with squamous cell carcinoma of the cervix, due to concomitant kidney pathology (chronic tubulointerstitial nephritis, gouty nephropathy, CKD C4 according to the KDIGO classification) has contraindications for iodinated contrast, hence contrast enhanced computed tomography (CT) and regular FDCT angiography. A native CT study revealed a hypodence 17 mm diameter lesion in SVII of the liver. US and MRI data were ambiguous. The presence of a clear hypervascular rim in the arterial and venous phases of dynamic contrast enhancement could not rule out the metastasis. In order to clarify the nature of the lesion in the liver, multidisciplinary team suggested biopsy under digital subtraction angiography and FDCT arteriohepaticography using CO2 as a contrast agent because of the risk of the haemorrage. For this purpose, using the Seldinger technique, through right femoral artery, by means of an Artis Zee angiographic unit (Siemens, Germany) catheterization and gas subtraction angiography of the common hepatic artery were performed. FDCT-CO2-arteriohepaticography of the common hepatic artery was performed afterwards using the same installation and injecting 30 ml of carbon dioxide at the rate of 3 ml/sec (special «Angiodroid» (Italy) CO2 injector was used) and a scanning delay of 3 sec (in 6sDCT Body mode).RESULTS: Вy means of subtraction CO2-arteriohepaticography and FDCT arteriohepaticography using CO2 in SVII of the liver the solitary hypervascular 15 mm lesion was detected. In order to verify the lesion single-shot US and FDCT-guided biopsy was performed. It was followed by a control FDCT arteriohepaticography using CO2 to exclude bleeding. Histopathology refuted metastasis.CONCLUSION: CO2 is a safe contrast agent in patients with renal failure and allergies to iodinated contrast agents. FDCT CO2 arteriohepaticography is an effective alternative method, that allows safe visualization and bleeding control after interventions in patient with renal failure.